This approach is currently being evaluated in a phase I clinical trial, which aims to assess the efficacy of combination NY‐ESO‐1 TCR engineered haematopoietic stem cells with NY‐ESO‐1TCR‐engineered T cells across a range of cancer types (NCT03691376, Table 2). Here, CTAG1B is linked to cancer.